Laurie Barclay, MD Oct. 16, 2002
In a head-to-head trial presented as a poster at a mental health specialty meeting this week, escitalopram was about as effective as venlafaxine in treating major depressive disorder (MDD). Presenter Stuart Montgomery, from the Imperial College School of Medicine at the University of London, also suggested that escitalopram may have a faster onset of action, fewer adverse effects, and better tolerability.
“Escitalopram is a potent and highly selective serotonin reuptake inhibitor, the efficacy and safety of which have recently been established in MDD,” the authors write.”
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!